Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Targeting p53 as a promising therapeutic option for cancer by re-activating the wt or mutant p53's tumor suppression.

Węsierska-Gądek J.

Future Med Chem. 2018 Apr 1;10(7):755-777. doi: 10.4155/fmc-2017-0175. Epub 2018 Mar 23. Review.

PMID:
29569948
2.

Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond.

Węsierska-Gądek J, Mauritz M.

Future Med Chem. 2016 Jan;8(1):55-72. doi: 10.4155/fmc.15.155. Epub 2015 Dec 21. Review.

PMID:
26692095
3.

Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.

Węsierska-Gądek J, Mauritz M, Mitulovic G, Cupo M.

J Cell Biochem. 2015 Dec;116(12):2824-39. doi: 10.1002/jcb.25229.

PMID:
25981734
4.
5.

PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.

Węsierska-Gądek J, Zulehner N, Ferk F, Składanowski A, Komina O, Maurer M.

Biochem Pharmacol. 2012 Nov 15;84(10):1318-31. doi: 10.1016/j.bcp.2012.07.024. Epub 2012 Aug 14.

6.

The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.

Węsierska-Gądek J, Kramer MP.

Future Med Chem. 2012 Mar;4(4):395-424. doi: 10.4155/fmc.12.12. Review.

PMID:
22416772
7.

Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.

Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H, Pirker C, Komina O, Węsierska-Gądek J, Haitel A, Filipits M, Berger W, Schmid K.

Neuroendocrinology. 2012;96(3):228-37. doi: 10.1159/000337257. Epub 2012 Apr 27.

PMID:
22378048
8.

Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.

Węsierska-Gądek J, Składanowski A.

Future Med Chem. 2012 Jan;4(1):51-72. doi: 10.4155/fmc.11.175. Review.

PMID:
22168164
9.

Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.

Żołnierczyk JD, Komina O, Błoński JZ, Borowiak A, Cebula-Obrzut B, Smolewski P, Robak P, Kiliańska ZM, Węsierska-Gądek J.

Med Oncol. 2012 Sep;29(3):2111-26. doi: 10.1007/s12032-011-0105-8. Epub 2011 Nov 16.

PMID:
22086735
10.

The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.

Węsierska-Gądek J, Kramer MP.

Expert Opin Investig Drugs. 2011 Dec;20(12):1611-28. doi: 10.1517/13543784.2011.628985. Epub 2011 Oct 21. Review.

PMID:
22017180
11.
12.

Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.

Węsierska-Gądek J, Gritsch D, Zulehner N, Komina O, Maurer M.

J Cell Biochem. 2011 Mar;112(3):761-72. doi: 10.1002/jcb.23004.

PMID:
21328450
13.

Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.

Węsierska-Gądek J, Gritsch D, Zulehner N, Komina O, Maurer M.

J Cell Biochem. 2011 Apr;112(4):1103-17. doi: 10.1002/jcb.23024.

PMID:
21308739
14.

Combining an FPTase inhibitor with cisplatin facilitates induction of apoptosis in human A549 lung cancer cells.

Weber F, Siska P, Kramer M, Zulehner N, Hackl S, Wesierska-Gádek J.

J Exp Ther Oncol. 2011;9(1):53-65.

PMID:
21275266
15.
16.

Roscovitine, a small molecule CDK inhibitor induces apoptosis in multidrug-resistant human multiple myeloma cells.

Komina O, Nosske E, Maurer M, Wesierska-Gadek J.

J Exp Ther Oncol. 2011;9(1):27-35.

PMID:
21275263
17.
18.
19.

mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging.

Wesierska-Gadek J.

Aging (Albany NY). 2010 Dec;2(12):892-3. No abstract available.

20.

Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.

Węsierska-Gądek J, Hackl S, Zulehner N, Maurer M, Komina O.

J Cell Biochem. 2011 Jan;112(1):273-88. doi: 10.1002/jcb.22918.

PMID:
21080333
21.

Whether to target single or multiple CDKs for therapy? That is the question.

Węsierska-Gądek J, Maurer M, Zulehner N, Komina O.

J Cell Physiol. 2011 Feb;226(2):341-9. doi: 10.1002/jcp.22426.

PMID:
20836132
22.

[Biological activity of poly(ADP-ribose)polymerase-1].

Kiliańska ZM, Zołnierczyk J, Wesierska-Gadek J.

Postepy Hig Med Dosw (Online). 2010 Jul 30;64:344-63. Review. Polish.

23.

Tubulohelical membrane arrays: From the initial observation to the elucidation of nanophysical properties and cellular function.

Reipert S, Wesierska-Gadek J, Wienerroither S.

PMC Biophys. 2010 Jun 28;3(1):13. doi: 10.1186/1757-5036-3-13.

24.
25.

Novel potent pharmacological cyclin-dependent kinase inhibitors.

Węsierska-Gądek J, Chamrád I, Kryštof V.

Future Med Chem. 2009 Dec;1(9):1561-81. doi: 10.4155/fmc.09.110. Review.

PMID:
21425979
26.

R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis.

Rogalińska M, Błoński JZ, Komina O, Góralski P, Zołnierczyk JD, Piekarski H, Robak T, Kiliańska ZM, Wesierska-Gadek J.

J Cell Biochem. 2010 Jan 1;109(1):217-35. doi: 10.1002/jcb.22400.

PMID:
19911397
27.

Oncogenes do not Fully Override Cell-intrinsic Traits: Pronounced Impact of the Cellular Programme.

Węsierska-Gądek J, Walzi E, Dolečkova I, Schmid G.

Cancer Microenviron. 2009 Sep 4;2(Suppl 1):215-25. doi: 10.1007/s12307-009-0024-9. eCollection 2009 Sep.

28.

Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.

Wesierska-Gadek J, Borza A, Komina O, Maurer M.

Acta Biochim Pol. 2009;56(3):495-501. Epub 2009 Aug 31.

29.

Monitoring of long-term effects of resveratrol on cell cycle progression of human HeLa cells after administration of a single dose.

Kramer MP, Wesierska-Gadek J.

Ann N Y Acad Sci. 2009 Aug;1171:257-63. doi: 10.1111/j.1749-6632.2009.04884.x.

PMID:
19723063
30.

Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells.

Maurer M, Komina O, Wesierska-Gadek J.

Ann N Y Acad Sci. 2009 Aug;1171:250-6. doi: 10.1111/j.1749-6632.2009.04717.x.

PMID:
19723062
31.

Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?

Wandl S, Wesierska-Gadek J.

Ann N Y Acad Sci. 2009 Aug;1171:242-9. doi: 10.1111/j.1749-6632.2009.04700.x.

PMID:
19723061
32.

Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?

Wesierska-Gadek J, Krystof V.

Ann N Y Acad Sci. 2009 Aug;1171:228-41. doi: 10.1111/j.1749-6632.2009.04726.x. Review.

PMID:
19723060
33.

Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.

Zolnierczyk JD, Błoński JZ, Robak T, Kiliańska ZM, Wesierska-Gadek J.

Ann N Y Acad Sci. 2009 Aug;1171:124-31. doi: 10.1111/j.1749-6632.2009.04903.x.

PMID:
19723046
34.

Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.

Paprskárová M, Krystof V, Jorda R, Dzubák P, Hajdúch M, Wesierska-Gadek J, Strnad M.

J Cell Biochem. 2009 Jun 1;107(3):428-37. doi: 10.1002/jcb.22139.

PMID:
19308936
35.

Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment.

Wesierska-Gadek J, Borza A, Walzi E, Krystof V, Maurer M, Komina O, Wandl S.

J Cell Biochem. 2009 Apr 1;106(5):937-55. doi: 10.1002/jcb.22074.

PMID:
19180585
36.

p53-mediated regulation of cell cycle progression: pronounced impact of cellular microenvironment.

Schmid G, Kramer MP, Wesierska-Gadek J.

J Cell Physiol. 2009 May;219(2):459-69. doi: 10.1002/jcp.21705.

PMID:
19170070
37.

Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells.

Wesierska-Gadek J, Wandl S, Kramer MP, Pickem C, Krystof V, Hajek SB.

J Cell Biochem. 2008 Dec 1;105(5):1161-71. doi: 10.1002/jcb.21903.

PMID:
18846503
38.

Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells.

Wesierska-Gadek J, Hajek SB, Sarg B, Wandl S, Walzi E, Lindner H.

Biochem Pharmacol. 2008 Dec 1;76(11):1503-14. doi: 10.1016/j.bcp.2008.07.040. Epub 2008 Aug 12.

PMID:
18761330
39.

Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells.

Komina O, Wesierska-Gadek J.

Biochem Pharmacol. 2008 Dec 1;76(11):1554-62. doi: 10.1016/j.bcp.2008.08.002. Epub 2008 Aug 12.

PMID:
18761329
40.

[New face of antiapoptotic proteins. II. Survivin].

Wesierska-Gadek J, Bednarek J, Kiliańska ZM.

Postepy Biochem. 2007;53(3):239-53. Polish.

PMID:
18399352
41.

[New face of antiapoptotic proteins. I. Protein Mcl-1].

Bednarek J, Wesierska-Gadek J, Kiliańska ZM.

Postepy Biochem. 2007;53(3):228-38. Review. Polish.

PMID:
18399351
43.

A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein.

Wesierska-Gadek J, Gueorguieva M, Kramer MP, Ranftler C, Sarg B, Lindner H.

J Cell Biochem. 2007 Dec 15;102(6):1405-19.

PMID:
17975794
44.

Characterization of the antibodies to p62 nucleoporin in primary biliary cirrhosis using human recombinant antigen.

Wesierska-Gadek J, Klima A, Ranftler C, Komina O, Hanover J, Invernizzi P, Penner E.

J Cell Biochem. 2008 May 1;104(1):27-37.

PMID:
17960595
45.

Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.

Wesierska-Gadek J, Kramer MP, Maurer M.

Food Chem Toxicol. 2008 Apr;46(4):1327-33. Epub 2007 Sep 11.

PMID:
17933449
46.

Signaling of DNA damage is not sufficient to induce p53 response: (re)activation of wt p53 protein strongly depends on cellular context.

Wesierska-Gadek J, Gueorguieva M, Komina O, Schmid G, Kramer MP.

J Cell Biochem. 2008 Apr 1;103(5):1607-20.

PMID:
17879942
47.

Characterization of autoantibodies against components of the nuclear pore complexes: high frequency of anti-p62 nucleoporin antibodies.

Wesierska-Gadek J, Klima A, Komina O, Ranftler C, Invernizzi P, Penner E.

Ann N Y Acad Sci. 2007 Aug;1109:519-30.

PMID:
17785341
48.

Cellular and organismal ageing: Role of the p53 tumor suppressor protein in the induction of transient and terminal senescence.

Schmid G, Kramer MP, Maurer M, Wandl S, Wesierska-Gadek J.

J Cell Biochem. 2007 Aug 15;101(6):1355-69. Review.

PMID:
17471501
49.

Inhibition of farnesyl protein transferase sensitizes human MCF-7 breast cancer cells to roscovitine-mediated cell cycle arrest.

Wesierska-Gadek J, Maurer M, Schmid G.

J Cell Biochem. 2007 Oct 15;102(3):736-47.

PMID:
17415788
50.

Effect of distinct anticancer drugs on the phosphorylation of p53 protein at serine 46 in human MCF-7 breast cancer cells.

Wesierska-Gadek J, Gueorguieva M, Herbacek I, Ranftler C.

Ann N Y Acad Sci. 2007 Jan;1095:45-52.

PMID:
17404016

Supplemental Content

Loading ...
Support Center